Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05887037
Other study ID # KY2023-018-02
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 1, 2022
Est. completion date July 1, 2025

Study information

Verified date October 2023
Source Capital Medical University
Contact Jian-Xin Zhou, MD
Phone 8610 63926888
Email zhoujx.cn@icloud.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the current study was to assess the economic impact of using metagenomic next-generation sequencing (mNGS) versus traditional bacterial culture directed CNSIs diagnosis and therapy in post-neurosurgical patients from Beijing Tiantan Hospital. mNGS is a relatively expensive test item, and whether it has the corresponding health economic significance in the clinical application of diagnosing intracranial infection has not been studied clearly. Therefore, the investigators hope to explore the clinical application value of mNGS detection in central nervous system infection after neurosurgery.


Description:

Central nervous system infections (CNSIs) are severe complications after neurosurgery, that can lead to a poor prognosis. The incidence of postoperative central nervous system infections (PCNSIs) ranges from 2.8% to 14%, and there are differences between different regions. The incidence rate in developed countries is lower than that in developing countries. The most common manifestations of PCNSIs include meningitis, ventriculitis, subdural abscess, epidural abscesses, and brain abscesses. Studies have shown that the most common pathogens of PCNSIs are Staphylococcus aureus, and coagulase-negative staphylococcus, followed by gram-negative bacteria. In China, the pathogen detection rate of traditional cerebrospinal fluid (CSF) culture can only reach 5.4-10%. In addition, culture as the gold standard is time-consuming and susceptible to the use of antibiotics. PCNSIs is related to increased treatment costs, prolonged hospitalization time, psychological trauma and delayed postoperative adjuvant treatment, which places a substantial economic and psychological burden on society and patients' families. Given the seriousness of PCNSIs, it is challenging to choose the appropriate antibiotic treatment for PCNSIs and should be guided by pathogens and their drug sensitivity. Thus, early and efficient diagnosis of pathogens is crucial for PCNSIs. Compared with traditional pathogenic microbial detection methods, metagenomic next-generation sequencing (mNGS) has faster, more accurate, and more complete advantages. Currently, it is widely used in CNSIs, respiratory infections, blood infections, etc., especially suitable for the diagnosis of acute, critical, and complicated infections. Studies have shown that the positive rate of mNGS is much higher than that of culture, and it is less affected by the use of antibiotics, which can provide more accurate feedback on the patient's infection status. At the same time, it can detect a variety of pathogen types, providing more effective guidance for treatment. In addition, the fast detection speed of mNGS can effectively shorten the patient's course of the disease and significantly improve the prognosis of infected patients. Most published mNGS studies are evaluations of their clinical diagnostic value. However, there is still some controversy over the full clinical use of mNGS, and one of the main reasons is cost constraints. The overall cost of mNGS detection reagents and labor in each sample is much higher than that of traditional detection methods. There are still no reports on health economics research on the use of mNGS to diagnose CNSIs after neurosurgery. Therefore, prospective clinical trials are needed to evaluate the cost-effectiveness of mNGS, a relatively expensive new detection method. In summary, this study intends to conduct a health economics study of mNGS to diagnose postoperative central nervous system infections and evaluate whether mNGS, as a relatively expensive new technology, can identify the pathogen at the early stage, shorten the time of anti-infective treatment, reduce the overall medical cost, and improve the cure rate of patients. In addition, this study provides theoretical guidance for clinical and public health departments to make cost-effective decisions more scientifically, make more effective use of medical resources, and improve the social and economic benefits of etiological diagnosis.


Recruitment information / eligibility

Status Recruiting
Enrollment 204
Est. completion date July 1, 2025
Est. primary completion date June 20, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: ·Central nervous system infections Exclusion Criteria: - Unqualified samples - Patients and their families refused to sign the informed consent - The clinician considered the case unsuitable for inclusion in the study

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
mNGS
mNGS is the direct extraction of nucleic acid from clinical samples. High-throughput sequencing technology and bioinformatics analysis were adopted to complete the detection of pathogens such as bacteria, fungi, viruses and parasites at one time
The traditional microbiological cultures
Traditional microbial culture is the gold standard for the diagnosis of central nervous system infection, but the traditional microbiological culture time is long and the detection rate is low.

Locations

Country Name City State
China Linlin Zhang Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Jian-Xin Zhou

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incremental cost effectiveness ratio Measures the increased cost for each unit of mortality reduction or increase in cure rate up to 12 weeks
Secondary Cost comparison The difference in total cost between the mNGS group (experimental group) and the etiology culture group (control group) was compared, and the time cost, detection cost, anti-infection treatment-related cost and other costs were calculated respectively. up to 12 weeks
Secondary Efficacy comparison The cure rate and mortality rate of central nervous system infection in the experimental group, and the control group were compared. up to 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT02506686 - Meropenem Penetration Across BBB in Patients With CNS Infection and Optimization of Meropenem Treatment Phase 4
Active, not recruiting NCT02017665 - Singapore Neurologic Infections Program N/A
Completed NCT01431326 - Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Completed NCT01520597 - National Study on Listeriosis and Listeria
Not yet recruiting NCT06358209 - Safety and Efficacy of Ventricular Irrigation for Ventriculitis N/A
Not yet recruiting NCT06412549 - Effect of a Bundle of Interventions on the Outcomes of Patients With Intracranial Devices (ICP Monitor e EVD) N/A
Active, not recruiting NCT03776994 - Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine Phase 1
Active, not recruiting NCT04737785 - Central Nervous System Disorders Following Hematopoietic Stem Cell Transplantation
Recruiting NCT03418441 - Central Nervous System Infections in Denmark
Recruiting NCT06418048 - INfectious DIsease REgistry BIObank
Active, not recruiting NCT06412523 - Device-related Central Nervous System Infections in Adult Intensive Care Units in Brazil
Active, not recruiting NCT02334670 - Vietnam Cryptococcal Retention in Care Study Version 1.0 N/A
Completed NCT04796935 - A Study to Test Performance of Needle Placements for Neuraxial Procedures Using Tactile Imaging vs Control N/A
Not yet recruiting NCT04229511 - Development of Risk Score Model and Decision Tree Algorithm for Predicting Infections With CRKp in Colonized Patients